Witjes - Figure 25
Sequential Intravesical Therapy
FIG. 25: A larger EORTC Genito-Urinary Group study[13] also compared BCG vs mitomycin plus BCG in patients with carcinoma in situ and reported findings similar to ours (in the previous Figure).[12] Toxicity was comparable and efficacy was not significantly different (although the combination therapy was slightly more effective).
References
Witjes JA, Caris CT, Mungan NA, et al. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol. 1998;160:1668−71 http://dx.doi.org/10.1016/S0022-5347(01)62377-2
Oosterlinck W, Kirkali Z, Sylvester R, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). Eur Urol. 2011;59:438−46 http://dx.doi.org/10.1016/j.eururo.2010.11.038
